Tislelizumab a programmed death ligand 1 (PD-L1)/programmed death ligand 2 (PD-L2)–mediated cell signaling antagonist, can increase cytokine production and restore T-cell activation, resulting in immune-mediated tumor cell death (9). This evidence concerns the gene PDCD1LG2 and neoplasm.